🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

445 results for “SK” Clear

  1. Behavioral Drug and Risk Counseling (BDRC)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Risk Behaviors

    phase 2 other completed

    1 trial

  2. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  3. CAPECITABINE , VALPROIC ACID

    Fondazione Telethon ETS

    low- risk rectal cancel

    phase 2 small molecule active

    1 trial

  4. CARDIOASPIRIN 100 mg Compresse gastroresistenti, Tabex 1,5 mg tabletki powlekane

    Fondazione Telethon ETS

    Subjects at high risk of inflammatory state and mortality from lung cancer, other cancers and all causes

    phase 2 small molecule active

    1 trial

  5. CEMIPLIMAB

    Fondazione Telethon ETS

    surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. ChAdOx1-MVA 5T4 vaccine

    Barinthus Biotherapeutics plc.

    Intermediate Risk Prostate Cancer

    phase 2 mab terminated

    1 trial

  7. Citanest® Dental Octapressin 30 mg/ml + 0,03 IE/ml, Xylocain ®Dental adrenalin 20 mg/ml + 12,5 mikrog/ml Injeksjonsvæske, oppløsning i sylindretter

    Lacuna Pharma Pty Ltd

    Subjects having local anesthesia for dental procedures.

    phase 2 small molecule active

    1 trial

  8. Computerized tasks

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  9. Cretostimogene Grenadenorepvec

    CG Oncology

    High-Risk Non-Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  10. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  11. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  12. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  13. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  14. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  15. Determine the ED50 and ED95 of esketamine

    The First People's Hospital of Lianyungang

    Intrauterine Polyp

    phase 2 small molecule active

    1 trial

  16. Dinutuximab

    Children's Hospital of Fudan University

    High Risk Neuroblastoma

    phase 2 mab active

    1 trial

  17. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  18. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  19. EXEMESTANE, ANASTROZOLE, LETROZOLE

    Ningbo Cancer Hospital

    Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

    phase 2 small molecule active

    1 trial

  20. EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN

    Ningbo Cancer Hospital

    Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.

    phase 2 small molecule active

    1 trial

  21. Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulmonary environment through extracellular vesicles, advanced and functional imaging

    Fondazione Telethon ETS

    Patients with connective tissue diseases at high risk of interstial lung disease

    phase 2 other active

    1 trial

  22. FF/GSK573719

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  23. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

  24. GSK Biologicals' GSK2340274A (two different formulations)

    GlaxoSmithKline

    Influenza

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources